Frank Armstrong
Director/Board Member presso ECO ANIMAL HEALTH GROUP PLC
Patrimonio netto: 126 673 $ in data 31/03/2024
Provenienza dei contatti di primo grado di Frank Armstrong
| Entità | Tipo di entità | Settore Industriale | |
|---|---|---|---|
The Royal College of Physicians
128
| College/University | Other Consumer Services | 128 |
24
| Public Company | Pharmaceuticals: Major | 24 |
| Public Company | Pharmaceuticals: Major | 21 | |
The University of Edinburgh
19
| College/University | Other Consumer Services | 19 |
| Subsidiary | Pharmaceuticals: Major | 19 | |
Summit Therapeutics Ltd.
 Summit Therapeutics Ltd. Pharmaceuticals: MajorHealth Technology Summit Therapeutics Ltd. operates as a holding company, which engages in the discovery, development, and commercialization of antibiotic medicines. The company seeks to expand its product candidate portfolio through the development of new mechanism and precision antibiotics. Summit Therapeutics was founded by Stephen Graham Davies and Kay Dame Davies in January 2003 and is headquartered in Abingdon, the United Kingdom.
19
| Subsidiary | Pharmaceuticals: Major | 19 |
| Unknown | 14 | ||
Avidex Ltd.
 Avidex Ltd. Pharmaceuticals: MajorHealth Technology Avidex Ltd. develops and discovers drugs for the treatment of cancer and autoimmune diseases. The company develops small molecule and protein therapeutics involving T cell receptors. Avidex was founded in 1999 and is headquartered in Abingdon, UK
12
| Extinct | Pharmaceuticals: Major | 12 |
| Public Company | Biotechnology | 11 | |
Fulcrum Pharma Plc
 Fulcrum Pharma Plc Pharmaceuticals: OtherHealth Technology Fulcrum Pharma Plc provides drug development and regulatory expertise essential to progress a development program from research to product approval. The company was founded in 1999 and is headquartered in Hemel Hempstead, the United Kingdom.
8
| Extinct | Pharmaceuticals: Other | 8 |
| Public Company | Pharmaceuticals: Major | 7 | |
Bloomsbury Genetic Therapies Ltd.
 Bloomsbury Genetic Therapies Ltd. BiotechnologyHealth Technology Bloomsbury Genetic Therapies Ltd. is a British biotechnology company that specializes in developing gene therapy technologies for neurological and metabolic diseases. The company is based in Cambridge, UK. Bloomsbury Genetic Therapies was founded in 2021 by Adrien Lemoine, who has been the CEO since 2021.
6
| Holding Company | Biotechnology | 6 |
Merck Serono SA
 Merck Serono SA Medical SpecialtiesHealth Technology Merck Serono SA operates as a holding company in the pharmaceutical field. It engages in the research, development, manufacture, and distribution of therapeutic products for the treatment of human diseases. The company was founded on May 21, 1987 and is headquartered in Coinsins, Switzerland.
5
| Subsidiary | Medical Specialties | 5 |
BioCaptiva Ltd.
 BioCaptiva Ltd. BiotechnologyHealth Technology BioCaptiva Ltd. is a British medical device company that is developing the BioCaptis, a device that can transform liquid biopsy testing for cancer management. The company is based in Edinburgh, UK. The BioCaptis captures up to 100x more cell-free DNA (cfDNA) than a venous blood draw, yielding high-quality and quantity cfDNA for testing, which addresses the major challenge of liquid biopsy in cancer management. This will potentially allow the testing of a far greater number of cancer types and stages in a much wider range of patients. BioCaptiva was founded in 2021 when it spun out from the University of Edinburgh. The CEO is Jeremy Wheeler.
5
| Holding Company | Biotechnology | 5 |
Newcells Biotech Ltd.
 Newcells Biotech Ltd. BiotechnologyHealth Technology Newcells Biotech Ltd. operates as a biotechnology company which produces induced pluripotent stem cells and reproducible cell and tissues. Its cell products include human neural progenitor and cardiomyocyte. The firm also provides reprogramming and differentiation services and products. The company was founded by Majlinda Lako and Lyle Armstrong in 2014 and is headquartered in Newcastle Upon Tyne, the United Kingdom.
3
| Holding Company | Biotechnology | 3 |
Pharmaron Abs, Inc.
 Pharmaron Abs, Inc. Pharmaceuticals: MajorHealth Technology Xceleron, Inc. provides drug development and biomedical research services. Its services include pharmaceutical and analytical method quality. The company was founded by Colin Garner in 1997 and is headquartered in Germantown, MD.
2
| Subsidiary | Pharmaceuticals: Major | 2 |
Asceneuron SA
 Asceneuron SA Pharmaceuticals: MajorHealth Technology Asceneuron SA operates as a biotechnology company. It develops therapeutics for orphan tauopathis and Alzheimer?s disease. The firm specializes in small molecule drug discovery for neurodegenerative diseases. The company was founded by Dirk Beher, Frank Murdoch Armstrong and Christoph Wiessner in October 2012 and is headquartered in Lausanne, Switzerland.
2
| Holding Company | Pharmaceuticals: Major | 2 |
Pharma Action GmbH
 Pharma Action GmbH Pharmaceuticals: MajorHealth Technology Part of Rethmann SE & Co. KG, Pharma Action GmbH is a German pharmaceutical company that manufactures pharmaceutical products. The private company is based in Berlin, Germany. The CEOs of the company are Erol Isim, Carl E. Bürger. Pharma Action was acquired by Bioibérica SA from Tönnies Lebensmittel GmbH & Co. KG on November 16, 2017.
2
| Subsidiary | Pharmaceuticals: Major | 2 |
Action Pharma A/S
 Action Pharma A/S BiotechnologyHealth Technology Action Pharma A/S is an R&D-focused biotech company located in the Nordic Medicon Valley area in Copenhagen, Denmark. Action Pharma was founded in 2000 and has a pipeline of 4 drug candidates in different stages of development, plus additional compounds in discovery and early preclinical development. Action Pharma pursues the discovery and development of new drugs and treatment concepts to treat cardiovascular diseases, inflammatory diseases and metabolic diseases, such as type-II diabetes and obesity. Its drug candidates are modified endogenous peptides with improved efficacy and small chemical entities targeted the melanocortin receptors. In disease models, its drug candidates have shown strong effects in treating and preventing inflammation and organ damage in conditions such as post-surgical organ dysfunction and acute myocardial infarction. A major focus for Action Pharma is treatment candidates for type-II diabetes, obesity and metabolic syndrome. Moreover, several drug candidates have shown effects in treating inflammatory diseases, such as rheumatoid arthritis, inflammatory bowel disease, multiple sclerosis and dermatitis.
1
| Extinct | Biotechnology | 1 |
University Court
1
| Private Company | 1 | |
Enhanc3D Genomics Ltd.
 Enhanc3D Genomics Ltd. BiotechnologyHealth Technology Enhanc3D Genomics is a private functional genomics company based in Cambridge, UK. Enhanc3D Genomics is developing a technology to unlock the full potential of the three-dimensional organization of the human genome. The British company's focus is on the non-coding regions of the genome, aiming to identify disease-associated genetic interactions and revolutionize target and biomarker discovery. The company's unique approach has the potential to make precision medicine an everyday reality for patients. Enhanc3D Genomics Ltd. was founded by Mikhail Spivakov, Peter Fraser, and Stefan Schönfelder. The CEO is Hazel Jones.
1
| Holding Company | Biotechnology | 1 |
1
| Subsidiary | Pharmaceuticals: Major | 1 |
Entelos, Inc.
 Entelos, Inc. Information Technology ServicesTechnology Services Entelos, Inc. develops predictive computer models of human disease. Its solutions include mechanism-based, mathematical models; virtual patients, populations; biosimulation software and biosimulation expertise. The company was founded in 1996 and is headquartered in San Mateo, CA.
1
| Subsidiary | Information Technology Services | 1 |
Grafico delle società connesse in secondo grado
Relazione in diverse aziende
Società connesse a Frank Armstrong tramite i suoi contatti personali
| Società | Settore | Persone collegate | Posizione principale |
|---|---|---|---|
| BRISTOL-MYERS SQUIBB COMPANY | Pharmaceuticals: Major | Corporate Officer/Principal Chief Tech/Sci/R&D Officer Chief Tech/Sci/R&D Officer Corporate Officer/Principal | |
| MERCK & CO., INC. | Pharmaceuticals: Major | General Counsel Corporate Officer/Principal | |
| ASTRAZENECA PLC | Pharmaceuticals: Major | Corporate Officer/Principal Corporate Officer/Principal Corporate Officer/Principal | |
Genzyme Corp.
 Genzyme Corp. Medical SpecialtiesHealth Technology Genzyme Corp. engages in development and manufacture of specialty therapeutic, surgical and diagnostic product. It serves in the areas of rare genetic diseases, multiple sclerosis, cardiovascular diseases and endocrinology. The company was founded on June 8, 1981 and is headquartered in Cambridge, MA. | Medical Specialties | Corporate Officer/Principal Corporate Officer/Principal Chief Tech/Sci/R&D Officer | |
| MANNKIND CORPORATION | Pharmaceuticals: Major | Chief Tech/Sci/R&D Officer Chairman | |
Phoqus Pharmaceuticals Plc
 Phoqus Pharmaceuticals Plc Pharmaceuticals: MajorHealth Technology Phoqus Pharmaceuticals Plc develops pharmaceutical products. It's product Chronocort that helps to treat the patients with cortisol deficiency such as congenital adrenal hyperplasia and Addison's diseases. The company was founded in 1998 and is located in West Malling, UK. | Pharmaceuticals: Major | Chief Executive Officer Chief Executive Officer | |
| HORIZON THERAPEUTICS PUBLIC LIMITED COMPANY | Pharmaceuticals: Major | Director/Board Member | |
| GSK PLC | Pharmaceuticals: Major | Chief Tech/Sci/R&D Officer Chief Tech/Sci/R&D Officer | |
| BIOTIE THERAPIES CORP | Pharmaceuticals: Major | Chairman Chief Tech/Sci/R&D Officer Director/Board Member | |
| National University of Singapore | College/University | Undergraduate Degree Corporate Officer/Principal Doctorate Degree | |
| University of Oxford | College/University | Undergraduate Degree Corporate Officer/Principal Corporate Officer/Principal Corporate Officer/Principal Doctorate Degree Doctorate Degree Doctorate Degree Graduate Degree | |
| Imperial College London | College/University | Doctorate Degree Undergraduate Degree Undergraduate Degree Graduate Degree Graduate Degree Masters Business Admin | |
Institute of Chartered Accountants in England & Wales
 Institute of Chartered Accountants in England & Wales Miscellaneous Commercial ServicesCommercial Services The Institute of Chartered Accountants in England & Wales ensures that its members, students, and affiliates maintain the highest standards of professional competency and conduct to protect the public interest. The non-profit company is based in London, UK, and has subsidiaries in the United Kingdom. With over 150,000 members, the institute provides technical information, helplines, and communities to its members. | Miscellaneous Commercial Services | Corporate Officer/Principal Corporate Officer/Principal | |
| The University of Manchester | College/University | Doctorate Degree Undergraduate Degree Undergraduate Degree | |
Parke-Davis & Co. Ltd.
 Parke-Davis & Co. Ltd. Pharmaceuticals: MajorHealth Technology Part of Pfizer Inc., Parke-Davis & Co. Ltd. is a British pharmaceutical company. The private company is based in St. Helier, UK. | Pharmaceuticals: Major | Chief Tech/Sci/R&D Officer Corporate Officer/Principal | |
| University of Cambridge | College/University | Doctorate Degree Doctorate Degree Masters Business Admin Graduate Degree Undergraduate Degree | |
| McGill University | College/University | Undergraduate Degree Graduate Degree | |
| University of Leeds | College/University | Doctorate Degree Doctorate Degree | |
| University of Hong Kong | College/University | Doctorate Degree Doctorate Degree Undergraduate Degree Undergraduate Degree | |
| University of London | College/University | Doctorate Degree Undergraduate Degree Doctorate Degree Undergraduate Degree Doctorate Degree | |
| University of Uppsala | College/University | Doctorate Degree Corporate Officer/Principal | |
LEO Pharma A/S
 LEO Pharma A/S Pharmaceuticals: MajorHealth Technology LEO Pharma A/S develops, manufactures and markets drugs within the area of dermatology and critical care medicine. It supplies medicines to patients suffering from skin infections and diseases such as psoriasis and eczema, thrombosis, kidney disease and cancer. The company was founded by August Kongsted and Anton Antons in 1908 and is headquartered in Ballerup, Denmark. | Pharmaceuticals: Major | Director/Board Member Corporate Officer/Principal | |
| Trinity College Dublin | College/University | Corporate Officer/Principal Corporate Officer/Principal | |
| University of Birmingham | College/University | Doctorate Degree Undergraduate Degree Masters Business Admin Graduate Degree | |
Organon Pharma (UK) Ltd.
 Organon Pharma (UK) Ltd. Pharmaceuticals: MajorHealth Technology Organon Pharma (UK) Ltd. develops and manufactures pharmaceuticals. It offers osteoarthritis pain treatment Arcoxia, cardiovascular medication Cozaar, HIV drug Crixivan and asthma treatment Singulair. It operates a research center specializing in the development of central nervous system disorder such as Alzheimer's disease, depression, anxiety and migrane. The company was founded in 1953 and is headquartered in Hoddesdon, the United Kingdom. | Pharmaceuticals: Major | Chief Tech/Sci/R&D Officer Corporate Officer/Principal | |
| University College London | College/University | Undergraduate Degree Undergraduate Degree Undergraduate Degree Undergraduate Degree | |
American College of Cardiology Foundation
 American College of Cardiology Foundation Medical/Nursing ServicesHealth Services American College of Cardiology Foundation provides cardiovascular education services. Its services include cardiac surgery, chronic angine, diabetes, geriatric cardiology and heart failure and cardiomyopathies. The company was founded by Franz Groedel, Robert P. Glover and Bruno Kisc in 1949 and is headquartered in Washington, DC. | Medical/Nursing Services | Corporate Officer/Principal Corporate Officer/Principal | |
Merck Research Laboratories Massachusetts LLC
 Merck Research Laboratories Massachusetts LLC Pharmaceuticals: MajorHealth Technology Part of Merck & Co., Inc., Merck Research Laboratories Massachusetts LLC is a pharmaceutical company that provides free medicines and adult vaccines to qualified patients through their Merck Patient Assistance Program. The private company is based in Boston, MA and is a part of Merck & Co., Inc. and its affiliates. The company also offers information about insurance coverage and financial assistance options for eligible patients. The company conducts clinical trials and provides medical information covering thousands of topics in all fields of medicine through their Merck Manuals. Additionally, they report on their commitment to operating responsibly to benefit society through their corporate responsibility program, which includes their environmental, social, and governance (ESG) report. Merck for Mothers is an initiative to create a world where no woman has to die giving life. | Pharmaceuticals: Major | Chief Tech/Sci/R&D Officer Director/Board Member | |
| American Academy of Pharmaceutical Physicians | Corporate Officer/Principal Director/Board Member | ||
Albireo Ltd.
 Albireo Ltd. Pharmaceuticals: MajorHealth Technology Albireo Ltd. develops therapies that address medical needs in the gastrointestinal and liver disease area. It is a biotechnology company that develops therapies that address unmet medical needs in the gastrointestinal area and liver disease area. The firm's programs include Cholestatic Liver Diseases; Bile Acid Mal-absorption; Type 2 Diabetes Mellitus; Atopic Dermatitis and Psoriasis; and Post-Operative Adhesions. The company was founded by Jan Peter Mattsson in February 2008 and is headquartered in London, the United Kingdom. | Pharmaceuticals: Major | Director/Board Member Director/Board Member | |
Vantia Ltd.
 Vantia Ltd. Miscellaneous Commercial ServicesCommercial Services Vantia Ltd. services to provide molecule agonists of vasopressin receptors. It offers healthcare improve clinical treatments through development and commercialization of innovative medicines. The company was founded by Robert Haigh and Chris Yea in 2008 and is headquartered in Southampton, the United Kingdom. | Miscellaneous Commercial Services | Director/Board Member Sales & Marketing | |
Spark Therapeutics Ireland Ltd.
 Spark Therapeutics Ireland Ltd. Pharmaceuticals: MajorHealth Technology Spark Therapeutics Ireland Ltd. develops new gene medicines to treat autosomal dominant genetic diseases. Its product RhoNova, is designed for the treatment of patients with rhodopsin linked autosomal dominant retinitis pigmentosa, a debilitating, progressive form of inherited blindness resulting from a diverse array of mutations in the RHO gene. The company was founded by Jane G. Farrar, Paul Kenna, and Gearóid Tuohy and is headquartered in Dublin, Ireland. | Pharmaceuticals: Major | Director/Board Member Founder | |
| CLOVIS ONCOLOGY, INC. | Pharmaceuticals: Major | Founder Chief Tech/Sci/R&D Officer | |
Albireo AB
 Albireo AB Pharmaceuticals: MajorHealth Technology Albireo AB operates as a biopharmaceutical company, which focuses on the development and potential commercialization of novel bile acid modulators. It helps treat orphan pediatric liver diseases and gastrointestinal disorders where the improper flow or absorption of bile causes serious medical conditions for which there is high unmet need. The company was founded by Per-Göran Gillberg and Jan Mattsson and is headquartered in Göteborg, Sweden. | Pharmaceuticals: Major | Director/Board Member Director/Board Member | |
Immodulon Therapeutics Ltd.
 Immodulon Therapeutics Ltd. BiotechnologyHealth Technology Part of Lifexx SA, Immodulon Therapeutics Ltd. is a late-stage clinical biotechnology company based in Uxbridge, UK. Immodulon is developing a highly differentiated cancer immunotherapy approach that primes the patient’s own innate immune system with the aim to significantly enhance the efficacy of a broad range of anti-cancer therapies, including chemotherapy and checkpoint inhibitors. The British company is developing imm-101, a heat-killed mycobacterium obuense, as a broad-spectrum immunomodulatory agent with the potential to treat a range of difficult-to-treat tumors including those considered to be immunologically “ cold, ” such as pancreatic cancer. Immodulon's imm-101 based immunotherapy complements other cancer therapies, including immune checkpoint inhibitors and chemotherapy. The private company is focused on developing safe and effective immunotherapy treatments. The company was founded in 2007 by Charles Akle, John L. Stanford. Gertjan Bartlema has been the CEO of the company since 2022. | Biotechnology | Director/Board Member | |
Kyowa Kirin Ltd.
 Kyowa Kirin Ltd. Pharmaceuticals: MajorHealth Technology Founded in 1998, Kyowa Kirin Ltd. is a British pharmaceutical company that develops, manufactures, and distributes pharmaceutical products. Part of Kirin Holdings Co., Ltd., the private company is based in London, UK. | Pharmaceuticals: Major | Chairman | |
| Birmingham City Hospital | Corporate Officer/Principal | ||
| D'Amore-Mckim School of Business | College/University | Masters Business Admin Masters Business Admin | |
Akamis Bio Ltd.
 Akamis Bio Ltd. BiotechnologyHealth Technology Akamis Bio Ltd. operates as a biotechnology company which develops novel therapeutics that addresses cancer and other clinically unmet diseases. Its products include Enadenotucirev, Espindolol and AbEnAd. The firm also develops treatments based upon the research phase vaccine platform PolySTAR, which combines recombinant viral vectors with polymers to shield them from the immune system, and the research phase adjuvant and immunotherapeutic platform PolyMAP, which combines polymers with synthetic adjuvants to significantly enhance the effectiveness of vaccines. The company was founded by Andrew Justin Stewart Coats and Stefan D. Anker on November 17, 2006 and is headquartered in Abingdon, the United Kingdom. | Biotechnology | Chief Tech/Sci/R&D Officer Corporate Officer/Principal | |
| The Royal College of Paediatrics & Child Health | College/University | Corporate Officer/Principal Corporate Officer/Principal | |
Mymedsandme Ltd.
 Mymedsandme Ltd. Packaged SoftwareTechnology Services Mymedsandme Ltd. develops web-based reportum solutions. It transforms pharmacovigilance process. The firm provides local deployment, direct reporting and security & compliance reportum solutions. The company was founded by Stephen John Powell, Andrew Richard Rut and Trevor Gordon Gibbs in 2011 and is headquartered in London, the United Kingdom. | Packaged Software | Founder | |
Orchard Therapeutics (Europe) Ltd.
 Orchard Therapeutics (Europe) Ltd. BiotechnologyHealth Technology Orchard Therapeutics (Europe) Ltd. researches on transformative gene therapies. Its services include stem cell technology, gene therapy, eradicating orphan diseases, and paediatric diseases. The company was founded by Andrea Spezzi and Nicolas Koebel on September 1, 2015 and is headquartered in London, the United Kingdom. | Biotechnology | Director/Board Member Founder | |
| ORCHARD THERAPEUTICS PLC | Pharmaceuticals: Major | Director/Board Member Corporate Officer/Principal Founder | |
| Royal Free Hospital Medical School | College/University | Doctorate Degree Doctorate Degree | |
| Charing Cross Hospital Medical School | College/University | Doctorate Degree Graduate Degree | |
Leyden Laboratories B.V.
 Leyden Laboratories B.V. Miscellaneous Commercial ServicesCommercial Services Leyden Laboratories B.V. is a biotechnology company based in Amsterdam, Netherlands. Leyden Labs aims to protect humanity from known and future viruses by targeting commonalities of viral families. The Dutch company has developed a portfolio of accessible intranasal product candidates that may provide people with the freedom to immediately protect themselves from and prevent the spread of many strains of respiratory viruses, including ones in the influenza and coronavirus families. The company's energetic team of world-renowned biotechnology veterans and fresh talent is dedicated to thinking differently to free humanity from the burden of respiratory viruses. Leyden Labs is backed with $200m by blue-chip investors Casdin Capital, GV (formerly Google Ventures), F-Prime Capital, Byers Capital/Brook Byers, SoftBank Investment Advisers, Invus, and Bluebird Ventures. The company was founded in June 2020 by Koenraad Wiedhaup, Jaap Goudsmit, Domenico Valerio, and Ronald H. P. Brus, with Koenraad Wiedhaup serving as the CEO since incorporation. | Miscellaneous Commercial Services | Director/Board Member | |
| Mytommorows | Director/Board Member |
Statistiche
Distribuzione geografica
| Regno Unito | 26 |
| Stati Uniti | 13 |
| Irlanda | 4 |
| Svezia | 3 |
| Paesi Bassi | 3 |
Settori
| Health Technology | 25 |
| Consumer Services | 18 |
| Commercial Services | 5 |
| Health Services | 2 |
| Technology Services | 2 |
Posizioni
| Director/Board Member | 391 |
| Corporate Officer/Principal | 287 |
| Independent Dir/Board Member | 100 |
| Chief Tech/Sci/R&D Officer | 100 |
| Chairman | 73 |
Contatti più connessi
| Insiders | |
|---|---|
| Chrisantha Nicholas Nonis | 47 |
| Martin Edwards | 38 |
| Ik King Tiong | 29 |
| Anders Olof Adolf Ekblom | 27 |
| Kei Siong Khoo | 23 |
| James Shannon | 22 |
| Belén Garijo López | 22 |
| Leopoldo Giampaolo Zambeletti | 22 |
| Warren Cooper | 21 |
| Peter John Fellner | 21 |
| Denise Scots-Knight | 20 |
| George Elston | 18 |
| Andrew Allen | 18 |
| Stephen Davies | 18 |
| Janice Brown | 17 |
- Borsa valori
- Insiders
- Frank Armstrong
- Connessioni Società
